BACKGROUND: 3'-18F-fluoro-3'-deoxy-fluorothymidine (18F-FLT), a nucleoside analog, could monitor effects of molecularly targeted therapeutics on tumor proliferation. METHODS: We tested whether (18)F-FLT positron emission tomography (PET) uptake changes are associated with antitumor effects of erlotinib in A431 xenografts or cetuximab in SCC1 xenografts. RESULTS: Compared with pretreatment FLT PET scans, 3 days of erlotinib in A431 reduced the standardized uptake value (SUV) by 18%, whereas placebo increased SUV by 1% (p = .005). One week of cetuximab in SCC1 reduced SUV by 62%, whereas placebo reduced SUV by 16% (p = .005). FLT uptake suppression following anti-epidermal growth factor receptor (EGFR) treatment was associated with reduced tumor thymidine kinase-1 (TK1) activity. In vitro TK1 knockdown studies confirmed the importance of TK1 activity on intracellular FLT accumulation suppression. CONCLUSIONS: 18F-FLT PET imaging detects tumor responses to EGFR-inhibitors within days of starting therapy. This technique may identify patients likely to benefit from EGFR-inhibitors early in their treatment course.
BACKGROUND:3'-18F-fluoro-3'-deoxy-fluorothymidine (18F-FLT), a nucleoside analog, could monitor effects of molecularly targeted therapeutics on tumor proliferation. METHODS: We tested whether (18)F-FLT positron emission tomography (PET) uptake changes are associated with antitumor effects of erlotinib in A431 xenografts or cetuximab in SCC1 xenografts. RESULTS: Compared with pretreatment FLT PET scans, 3 days of erlotinib in A431 reduced the standardized uptake value (SUV) by 18%, whereas placebo increased SUV by 1% (p = .005). One week of cetuximab in SCC1 reduced SUV by 62%, whereas placebo reduced SUV by 16% (p = .005). FLT uptake suppression following anti-epidermal growth factor receptor (EGFR) treatment was associated with reduced tumorthymidine kinase-1 (TK1) activity. In vitro TK1 knockdown studies confirmed the importance of TK1 activity on intracellular FLT accumulation suppression. CONCLUSIONS: 18F-FLT PET imaging detects tumor responses to EGFR-inhibitors within days of starting therapy. This technique may identify patients likely to benefit from EGFR-inhibitors early in their treatment course.
Authors: Martin Wagner; Ulrike Seitz; Andreas Buck; Bernd Neumaier; Stefan Schultheiss; Markus Bangerter; Martin Bommer; Frank Leithäuser; Edgar Wawra; Gerd Munzert; Sven N Reske Journal: Cancer Res Date: 2003-05-15 Impact factor: 12.701
Authors: Hubert Vesselle; John Grierson; Mark Muzi; Jeffrey M Pugsley; Rodney A Schmidt; Peter Rabinowitz; Lanell M Peterson; Eric Vallières; Douglas E Wood Journal: Clin Cancer Res Date: 2002-11 Impact factor: 12.531
Authors: Aren van Waarde; David C P Cobben; Albert J H Suurmeijer; Bram Maas; Willem Vaalburg; Erik F J de Vries; Pieter L Jager; Harald J Hoekstra; Philip H Elsinga Journal: J Nucl Med Date: 2004-04 Impact factor: 10.057
Authors: Andreas K Buck; Holger Schirrmeister; Martin Hetzel; Mareike Von Der Heide; Gisela Halter; Gerhard Glatting; Torsten Mattfeldt; Florian Liewald; Sven N Reske; Bernd Neumaier Journal: Cancer Res Date: 2002-06-15 Impact factor: 12.701
Authors: Meg Perumal; Radhakrishna G Pillai; Henryk Barthel; Julius Leyton; John R Latigo; Martin Forster; Fraser Mitchell; Ann L Jackman; Eric O Aboagye Journal: Cancer Res Date: 2006-09-01 Impact factor: 12.701
Authors: Dong M Shin; Sreenivas Nannapaneni; Mihir R Patel; Qiuying Shi; Yuan Liu; Zhengjia Chen; Amy Y Chen; Mark W El-Deiry; Jonathan J Beitler; Conor E Steuer; Steven M Roser; Adam M Klein; Taofeek K Owonikoko; Suresh S Ramalingam; Fadlo R Khuri; Zhuo G Chen; Nabil F Saba Journal: Clin Cancer Res Date: 2020-09-17 Impact factor: 12.531
Authors: Hanneke Stegeman; Johannes H Kaanders; Albert J van der Kogel; Mari Iida; Deric L Wheeler; Paul N Span; Johan Bussink Journal: Radiother Oncol Date: 2013-02-28 Impact factor: 6.280
Authors: Neale S Mason; Brian J Lopresti; James Ruszkiewicz; Xinxin Dong; Sonali Joyce; George Leef; Malabika Sen; Abdus S Wahed; Chester A Mathis; Jennifer R Grandis; Sufi M Thomas Journal: Am J Nucl Med Mol Imaging Date: 2013-01-05
Authors: Peter J O'Brien; Michelle Lee; Mary E Spilker; Cathy C Zhang; Zhengming Yan; Timothy C Nichols; Wenlin Li; Caroline H Johnson; Gary J Patti; Gary Siuzdak Journal: Cancer Metab Date: 2013-01-23